Georgia
Provider Communications
Anthem clinical criteria updates for specialty pharmacy are available
Access the clinical criteria document information.
Anthem’s prior authorization clinical review of non-oncology specialty pharmacy drugs will be managed by Anthem’s medical specialty drug review team. Drugs used for the treatment of Oncology will be managed by AIM Specialty Health® (AIM).
ING-CC-0033 |
Xolair (omalizumab) |
ING-CC-0042 |
Monoclonal Antibodies to Interleukin-17 |
ING-CC-0050 |
Monoclonal Antibodies to Interleukin-23 |
ING-CC-0124 |
Keytruda (pembrolizumab) |
ING-CC-0186 |
Margenza (margetuximab-cmkb) |
ING-CC-0209 |
Leqvio (inclisiran) |
ING-CC-0210 |
Enjaymo (sutimlimab-jome) |
ING-CC-0212 |
Tezspire (tezepelumab-ekko) |
ING-CC-0213 |
Voxzogo (vosoritide) |
Featured In:
May 2022 Anthem Provider News - Georgia